Friday, October 20, 2017 1:32:17 PM
Scheme: Genetic and Cellular Therapy Laboratories
Client: Undisclosed
Value: £18m
Description:
AHP were appointed as lead designer for the refurbishment of an existing distribution depot and associated offices. The refurbishment provided the client with state of the art genetic and cellular therapy, GMP manufacturing facilities in class D, C and B cleanroom laboratories with associated accommodation, including temperature-controlled quarantine storage, microbiology testing laboratories, process development laboratories, cryogenic shipping, secure data storage, administration offices, staff recreation and changing areas.
The design also included 4 rentable ‘hotel’ suites for start-up projects. Each self-contained unit includes laboratory and EM microbiology facilities, and administration space.
https://www.ahpltd.co.uk/genetherapy (photos and description)
https://www.ahpltd.co.uk/biotechnology (other designed laboratories)
* Below as text appeared long ago:
AHP are pleased to have been instructed by a leading Bio Science company in the development of a new commercial validated GMP compliant manufacturing facility and state of the art Research and Development Laboratories in South Cambridge. Our client has extensive experience in the development of cell-based therapeutics in the USA and are now developing the first commercial scale manufacturing facility in England.
The South Cambridge Site offers the opportunity for further expansion and the vision is for the development of a healthcare campus providing both manufacturing and patient treatment in the same locality.
.
Recent NWBO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM